Key Proteo, Inc.’s Post

𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔 𝒇𝒓𝒐𝒎 𝑾𝒊𝒍𝒔𝒐𝒏 𝑨𝒂𝒓𝒉𝒖𝒔 2024 𝑺𝒚𝒎𝒑𝒐𝒔𝒊𝒖𝒎 Steve Hahn, MD, PhD, our Chief Medical Officer and Co-Founder, presented updates on a large 22,000-sample pilot study for modernized newborn screening using Key Proteo’s Immuno-SRM. 𝑲𝒆𝒚 𝑻𝒂𝒌𝒆𝒂𝒘𝒂𝒚𝒔: ▪ APT7B peptide target quantified with very high sensitivity and specificity. ▪ Exceptionally low false positive rate and invalid rate. No true false negatives. ▪ Peptide concentrations stable across weight, gender, and ethnicity. ▪ LC-MS proteomics proven feasible for newborn screening of Wilson Disease from standard DBS specimens. Early detection and intervention is critical. Key Proteo’s Immuno-SRM technology reveals the previously undetectable using existing LC-MS workflows. Key Proteo is grateful to the Wilson Aarhus Symposium for featuring cutting-edge Wilson Disease research. Kudos to all presenters, attendees and organizers! #WilsonDisease #WilsonDiseaseAssociation #MedicalResearch #Proteomics #NewbornScreening #HealthcareInnovation #WilsonAarhus2024 #KeyProteo #EarlyDetection Get in touch with us at info@keyproteo.com www.keyproteo.com

Are you at #APHL2024? Visit us at booth #702 and learn how our rapid, scalable pioneering proteomic technology can help change the clinical course of treatable rare genetic disorders through early screening. Stop by and chat with Mark Willig, President and Chief Executive Officer or Laureen Haynes, Vice President of Business Development and Strategic Alliances to discuss potential strategic collaborations, pilot programs or other partnership opportunities. Couldn't make it to #Milwaukee? Email us at info@keyproteo.com Learn more at: www.keyproteo.com #APHL #APHL2024 #APHLNBS #PublicHealth #NewbornScreening #KeyProteo #Proteomics

Only 3 days until #APHL2024 and we’re looking forward to visiting with public health professionals and colleagues in Milwaukee! Expanding newborn screening programs to identify many treatable rare genetic conditions that often go undetected is now possible with Immuno-SRM. Come visit us at booth #702 to learn how our rapid, scalable pioneering proteomic technology can help change the clinical course of treatable rare genetic disorders through early screening. Interested in strategic collaborations, pilot programs or other partnership opportunities? Message Mark Willig, President and Chief Executive Officer or Laureen Haynes, Vice President of Business Development and Strategic Alliances directly to schedule a meeting time, or email us at info@keyproteo.com. Learn more at: www.keyproteo.com #APHL #APHL2024 #APHLNBS #PublicHealth #NewbornScreening #KeyProteo #Proteomics

Collaborate With Key Proteo To Enhance Newborn Screening Programs APHL’s 2024 Annual Conference is less than 2 weeks away and we’re looking forward to visiting with public health professionals and colleagues in Milwaukee! Come visit us at booth #702 to learn how our rapid, scalable pioneering proteomic technology can help change the clinical course of treatable rare genetic disorders through early screening. We welcome the opportunity to discuss potential collaborations, pilot programs and related opportunities to further enhance newborn screening programs. If interested in scheduling time to discuss, feel free to message Mark Willig, President and Chief Executive Officer or Laureen Haynes, Vice President of Business Development and Strategic Alliances directly. Learn more at www.keyproteo.com #APHL #APHL2024 #APHLNBS #PublicHealth #NewbornScreening #Proteomics #KeyProteo

Happy Lab Week! Key Proteo extends our gratitude to public health laboratory professionals worldwide. Despite often operating behind the scenes, we applaud your unwavering commitment to each day. Thank you for your efforts in promoting the well-being and safety of your communities.   When asked why they love working in Key Proteo’s clinical laboratory, Research Scientist Claire Klippel expressed, "I am passionate about providing new screening opportunities for rare diseases in pediatric patients that will change their clinical outcome for the better." Moumita Dutta, MSc,PhD, DABT, another of Key Proteo’s Research Scientists, also added, "I am passionate about finding cures for rare diseases and aspire to contribute to a future where generations can enjoy the beauty of the world." Learn more at: Key Proteo: www.keyproteo.com

Addressing the Limitations of Newborn Screening Programs. The statistic is jaw-dropping – 70% of genetic rare diseases start in childhood. While newborn screening has evolved into an effective public health program to enable early intervention for many conditions, unfortunately there are many treatable rare genetic disorders that current newborn screening programs do not test for, resulting in devastating outcomes for many individuals and their families afflicted by these disorders. At Key Proteo, we envision a world in which early intervention through early, enhanced detection is available for every child, everywhere. With our novel proteomics-based platform, we aim to improve early screening programs, with the goal that every newborn is screened for a wider range of treatable conditions. By focusing on these critical unmet needs, we are working to drive better outcomes for future generations. Join us on this journey, because no treatable genetic disorder should go unseen. Learn more at: Key Proteo: www.keyproteo.com #APHL #AssociationofPublicHealthLaboratories #PublicHealth #APHLNBS #NewbornScreening #KeyProteo #Proteomics #WilsonDisease #WilsonDiseaseAssociation #WiskottAldrichSyndrome #XLA #AdenosineDeaminaseDeficiency

We are thrilled to announce that Key Proteo has recently joined the Association of Public Health Laboratories as a new Silver Level Sustaining Member. We look forward to collaborating with APHL to help drive positive change in public health initiatives and outcomes in newborn screening and other appropriate programs. We’re also excited to join the APHL community next month at APHL’s 2024 Annual Conference - stop by and visit us at booth #702 to learn more about our advancements in Newborn Screening. Learn more about Key Proteo: www.keyproteo.com #APHL #AssociationofPublicHealthLaboratories #PublicHealth #APHLNBS #NewbornScreening #KeyProteo

While Key Proteo intended to submit its first newborn screening kit to the FDA on 3/29/24, a software issue was identified in the final review of the application and has delayed the submission. Key Proteo would like to acknowledge the delay and fully intends to submit once the issue is resolved. Learn more about Key Proteo at: www.keyproteo.com #KeyProteo #DeNovoClassification #NewbornScreening #RareDisease #WilsonDisease #WilsonDiseaseAssociation #WiskottAldrichSyndrome #WiskottAldrichFoundation #XLA #AdenosineDeaminaseDeficiency #ImmuneDeficiencyFoundation #Proteomics #Biotech #VentureCapital #LifeSciences #HealthTech #BioTechNews

KeyProteo's Innovative Advancements in Newborn Screening for Wilson's Disease Highlighted in Gastroenterology and Endoscopy News. Thank you #GastroenterologyandEndoscopyNews for highlighting our progress in advancing newborn screening for Wilson Disease. If undiagnosed at birth, this condition can lead to significant adverse effects on a child's health, underscoring the need for early detection and intervention. Through our collaboration with the Washington State Public Health Newborn Screening Laboratory and Seattle Children’s Research Institute, we have seen promising results in our large-scale pilot study. Our innovative technology has the potential to revolutionize public health screening for treatable rare genetic disorders and improve clinical outcomes for those affected by potentially devastating conditions. Link to article: https://lnkd.in/gCzyK-y7 Learn more about Key Proteo here: https://www.keyproteo.com/ #WilsonDisease  #WilsonDiseaseAssociation #NewbornScreening #PublicHealth #MedicalInnovation #KeyProteo  #GastroenterologyandEndoscopyNews  #Biotech  #VentureCapital #LifeSciences  #HealthTech  #BioTechNews